Alphabet, Editas and Bio Palette-backed genomic medicine developer Beam will raise $180m in an upsized initial public offering three years after being spun out of Harvard University.

Beam Therapeutics, a US-based genetic therapy developer backed by internet and technology group Alphabet, priced its shares at $17.00 each for a $180m initial public offering today.

The company increased the number of shares in the offering from 9.25 million to nearly 10.6 million and is floating on the Nasdaq Global Select Market at the top of its $15 to $17 range.

Founded in 2017, Beam is working on treatments for serious diseases, exploiting genomic base editing technology able to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn